183 related articles for article (PubMed ID: 32547285)
1. Clinical Features, Therapeutic Trends, and Outcome of Giant Prolactinomas: A Single-Center Experience Over a 12-Year Period.
Almalki MH; Aljohani N; Alzahrani S; Almohareb O; Ahmad MM; Alrashed AA; Alshahrani F; Mahmood Buhary B
Clin Med Insights Endocrinol Diabetes; 2020; 13():1179551420926181. PubMed ID: 32547285
[TBL] [Abstract][Full Text] [Related]
2. Giant prolactinomas: clinical manifestations and outcomes of 16 Arab cases.
Almalki MH; Buhary B; Alzahrani S; Alshahrani F; Alsherbeni S; Alhowsawi G; Aljohani N
Pituitary; 2015 Jun; 18(3):405-9. PubMed ID: 25062894
[TBL] [Abstract][Full Text] [Related]
3. Giant prolactinomas in men: efficacy of cabergoline treatment.
Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
[TBL] [Abstract][Full Text] [Related]
4. Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review.
Huang HY; Lin SJ; Zhao WG; Wu ZB
Metab Brain Dis; 2018 Jun; 33(3):969-976. PubMed ID: 29546691
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of multimodal therapy for giant prolactinomas.
Andujar-Plata P; Villar-Taibo R; Ballesteros-Pomar MD; Vidal-Casariego A; Pérez-Corral B; Cabezas-Agrícola JM; Álvarez-Vázquez P; Serramito R; Bernabeu I
Endocrine; 2017 Jan; 55(1):231-238. PubMed ID: 27704480
[TBL] [Abstract][Full Text] [Related]
6. Giant prolactinomas: are they really different from ordinary macroprolactinomas?
Espinosa E; Sosa E; Mendoza V; Ramírez C; Melgar V; Mercado M
Endocrine; 2016 Jun; 52(3):652-9. PubMed ID: 26561015
[TBL] [Abstract][Full Text] [Related]
7. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
Shimon I; Sosa E; Mendoza V; Greenman Y; Tirosh A; Espinosa E; Popovic V; Glezer A; Bronstein MD; Mercado M
Pituitary; 2016 Aug; 19(4):429-36. PubMed ID: 27138902
[TBL] [Abstract][Full Text] [Related]
8. Restoration of fertility in a woman with giant prolactinoma in response to cabergoline treatment.
Astaf'eva LI; Sidneva YG; Kadashev BA; Kalinin PL; Melnichenko GA; Agadzhanian SA
Endocrinol Diabetes Metab Case Rep; 2019 Sep; 2019():. PubMed ID: 31967975
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of medical and surgical treatments in giant prolactinoma: a single-center experience.
Cander S; Oz Gul O; Eylemer E; Gullulu Boz E; Gunes E; Hakyemez B; Yilmazlar S; Ersoy C
Hormones (Athens); 2021 Sep; 20(3):491-498. PubMed ID: 34236607
[TBL] [Abstract][Full Text] [Related]
10. Giant prolactinomas: the therapeutic approach.
Moraes AB; Silva CM; Vieira Neto L; Gadelha MR
Clin Endocrinol (Oxf); 2013 Oct; 79(4):447-56. PubMed ID: 23662975
[TBL] [Abstract][Full Text] [Related]
11. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
12. Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up.
Wu ZB; Yu CJ; Su ZP; Zhuge QC; Wu JS; Zheng WM
J Neurosurg; 2006 Jan; 104(1):54-61. PubMed ID: 16509147
[TBL] [Abstract][Full Text] [Related]
13. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
14. Giant prolactinomas: clinical management and long-term follow up.
Shrivastava RK; Arginteanu MS; King WA; Post KD
J Neurosurg; 2002 Aug; 97(2):299-306. PubMed ID: 12186457
[TBL] [Abstract][Full Text] [Related]
15. Prolactinoma: Clinical Characteristics, Management and Outcome.
Irfan H; Shafiq W; Siddiqi AI; Ashfaq S; Attaullah S; Munir Alvi A; Khan SA; Abu Bakar M; Azmat U
Cureus; 2022 Oct; 14(10):e29822. PubMed ID: 36337795
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men.
Shimon I; Benbassat C; Hadani M
Eur J Endocrinol; 2007 Feb; 156(2):225-31. PubMed ID: 17287412
[TBL] [Abstract][Full Text] [Related]
17. Women with prolactinomas presented at the postmenopausal period.
Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
[TBL] [Abstract][Full Text] [Related]
18. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
19. Phenotype and resistance patterns of 10 resistant prolactinomas.
Araujo-Castro M; Abad López A; Aller Pardo J; Kanaan Kanaan L; Palacios García N
Endocrinol Diabetes Nutr (Engl Ed); 2020 Mar; 67(3):194-204. PubMed ID: 31201099
[TBL] [Abstract][Full Text] [Related]
20. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients.
Vroonen L; Jaffrain-Rea ML; Petrossians P; Tamagno G; Chanson P; Vilar L; Borson-Chazot F; Naves LA; Brue T; Gatta B; Delemer B; Ciccarelli E; Beck-Peccoz P; Caron P; Daly AF; Beckers A
Eur J Endocrinol; 2012 Nov; 167(5):651-62. PubMed ID: 22918301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
